Страна: Канада
мова: англійська
Джерело: Health Canada
METHYLPREDNISOLONE
PFIZER CANADA ULC
H02AB04
METHYLPREDNISOLONE
4MG
TABLET
METHYLPREDNISOLONE 4MG
ORAL
100
Prescription
ADRENALS
Active ingredient group (AIG) number: 0106290007; AHFS:
APPROVED
2003-09-19
_MEDROL (methylprednisolone) – Product Monograph _ _Page 1 of 32_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR MEDROL* methylprednisolone 4mg & 16mg tablets, for oral use USP Glucocorticoid Pfizer Canada ULC 17 300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Date of Initial Authorization: May 30, 2001 Date of Revision: MAR 12, 2024 Submission Control Number: 280540 * TM Pharmacia Enterprises S.A. Pfizer Canada ULC, licensee © Pfizer Canada ULC, 2023 _MEDROL (methylprednisolone) – Product Monograph _ _Page 2 of 32_ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, General, Endocrine and Metabolism 07/2023 8 ADVERSE REACTIONS 03/2024 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1. INDICATIONS ............................................................................................................... 4 1.1 Pediatrics ................................................................................................................ 5 1.2 Geriatrics ................................................................................................................ 5 2. CONTRAINDICATIONS ................................................................................................. 5 4. DOSAGE AND ADMINISTRATION ................................................................................. 6 4.1 Dosing Considerations ............................................................................................ 6 4.2 Recommended Dose and Dosage Adjustment ....................................................... 6 4.5 Missed Dose ........................................ Прочитайте повний документ